This review describes the identification of the cause of the disorder in the late 1980s—dystrophin deficiency—and the emerging therapeutics enabled by increased understanding of dystrophin structure and function. Here, DMD is linked to neuromuscular disease caused by qualitative or quantitative defects of dystrophin.